Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Taysha Gene Therapies, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PREVIOUSLY DISCLOSED 100% RESPONSE RATE ACROSS ALL 10 PATIENTS IN PART A FOR PIVOTAL TRIAL PRIMARY ENDPOINT OF GAIN/REGAIN OF  ONE NATURAL HISTORY DEFINED DEVELOPMENTAL MILESTONE ASSESSED VIA VIDEO-EVIDENCED REVIEW BY INDEPENDENT CENTRAL RATERS NEW SUPPLEMENTAL ANALYSIS OF VALIDATED, STRUCTURED EFFICACY SCALES PROVIDES SUPPORTIVE EVIDENCE OF ADDITIONAL FUNCTIONAL GAINS, WITH 100% OF PATIENTS DEMONSTRATING MULTIPLE SKILL GAINS/IMPROVEMENTS OUTSIDE THE NATURAL HISTORY DEFINED DEVELOPMENTAL MILESTONES FINDINGS REINFORCE THE BROAD AND CONSISTENT FUNCTIONAL GAINS SEEN ACROSS THE CORE DOMAINS THAT IMPACT ACTIVITIES OF DAILY LIVING, WITH 22 DEVELOPMENTAL MILESTONES AND 165 ADDITIONAL SKILLS/IMPROVEMENTS ACHIEVED ACROSS THE 10 PATIENTS POST-TSHA-102 DALLAS, OCT. 09, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED RESULTS FROM A NEW SUPPLEMENTAL DATA ANALYSIS FROM PART A OF THE REVEAL PHASE 1/2 ADULT/ADOLESCENT AND PEDIATRIC TRIALS EVALUATING TSHA-102 IN FEMALES WITH RETT SYNDROME AT THE 54TH CHILD NEUROLOGY SOCIETY (CNS) ANNUAL MEETING. THE ANALYSIS PROVIDES SUPPORTIVE EVIDENCE OF ADDITIONAL FUNCTIONAL GAINS IN SKILLS AND IMPROVEMENTS ACROSS CORE DISEASE CHARACTERISTICS THAT ARE OUTSIDE OF THE NATURAL HISTORY DEFINED DEVELOPMENTAL MILESTONES, FURTHER HIGHLIGHTING THE CONSISTENT, MULTI-DOMAIN IMPACT OF TSHA-102 ON ACTIVITIES OF DAILY LIVING.

TAYSHA GENE THERAPIES PRESENTS NEW SUPPLEMENTAL DATA ANALYSIS FROM PART A OF THE REVEAL PHASE 1/2 TRIALS FOR TSHA-102 IN RETT SYNDROME AT THE 54TH CNS ANNUAL MEETING

DALLAS, OCT. 03, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT, ON OCTOBER 1, 2025, THE COMPENSATION COMMITTEE OF TAYSHA'S BOARD OF DIRECTORS GRANTED SEVEN NEW EMPLOYEES, IN THE AGGREGATE, OPTIONS TO PURCHASE 1,289,600 SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THEIR EMPLOYMENT. THE STOCK OPTIONS WERE GRANTED UNDER THE TAYSHA GENE THERAPIES, INC. 2023 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE INDIVIDUALS ENTERING EMPLOYMENT WITH TAYSHA IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

TAYSHA GENE THERAPIES ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

BREAKTHROUGH THERAPY DESIGNATION GRANTED BASED ON FDA'S REVIEW OF AVAILABLE CLINICAL EVIDENCE OF SAFETY AND EFFICACY FROM ALL 12 PATIENTS TREATED IN PART A OF THE REVEAL PHASE 1/2 TRIALS FINALIZED FDA ALIGNMENT ON REVEAL PIVOTAL TRIAL PROTOCOL AND SAP FOLLOWING RESOLUTION OF REMAINING CLINICAL AND STATISTICAL QUERIES TO IND APPLICATION AMENDMENT; ON TRACK TO BEGIN PATIENT ENROLLMENT IN Q4 2025 KEY PIVOTAL TRIAL DESIGN ELEMENTS REMAIN UNCHANGED, INCLUDING 6-MONTH INTERIM ANALYSIS TO POTENTIALLY EXPEDITE BLA SUBMISSION BASED ON THE RIGOROUS DEVELOPMENTAL MILESTONE EVALUATION IN PART A SHOWING AN UNPRECEDENTED RESPONSE RATE AT 6 MONTHS POST-TSHA-102 THAT DEEPENED OVER TIME DALLAS, OCT. 02, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED BREAKTHROUGH THERAPY DESIGNATION TO TSHA-102, AN INTRATHECALLY DELIVERED AAV9 GENE THERAPY WITH DISEASE MODIFYING POTENTIAL, FOR THE TREATMENT OF RETT SYNDROME. ADDITIONALLY, THE COMPANY ANNOUNCED THAT IT HAS FINALIZED ALIGNMENT WITH THE FDA ON THE REVEAL PIVOTAL TRIAL PROTOCOL AND STATISTICAL ANALYSIS PLAN (SAP) THAT ARE INTENDED TO SUPPORT THE PLANNED BIOLOGICS LICENSE APPLICATION (BLA) SUBMISSION FOR TSHA-102, FOLLOWING THE RESOLUTION OF REMAINING CLINICAL AND STATISTICAL QUERIES.

TAYSHA GENE THERAPIES ANNOUNCES FDA BREAKTHROUGH THERAPY DESIGNATION AND PROVIDES POSITIVE REGULATORY UPDATE ON TSHA-102 IN RETT SYNDROME

DALLAS, SEPT. 05, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT, ON SEPTEMBER 2, 2025, THE COMPENSATION COMMITTEE OF TAYSHA'S BOARD OF DIRECTORS GRANTED FIVE NEW EMPLOYEES, IN THE AGGREGATE, OPTIONS TO PURCHASE 225,000 SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THEIR EMPLOYMENT. THE STOCK OPTIONS WERE GRANTED UNDER THE TAYSHA GENE THERAPIES, INC. 2023 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE INDIVIDUALS ENTERING EMPLOYMENT WITH TAYSHA IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

COMMENCED SITE ACTIVATION FOR REVEAL PIVOTAL TRIAL IN ACCORDANCE WITH PREVIOUSLY ALIGNED UPON KEY DESIGN ELEMENTS, FOLLOWING RECEIPT OF NO OBJECTION LETTER (NOL) FROM HEALTH CANADA AND FEEDBACK FROM THE FDA; PATIENT ENROLLMENT ANTICIPATED TO BEGIN IN Q4 2025

TAYSHA GENE THERAPIES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

DALLAS, AUG. 05, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC.(NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT IT WILL REPORT ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND HOST A CORPORATE UPDATE CONFERENCE CALL AND WEBCAST ON TUESDAY, AUGUST 12, 2025, AT 8:30 AM EASTERN TIME.

TAYSHA GENE THERAPIES TO RELEASE SECOND QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL AND WEBCAST ON AUGUST 12

DALLAS, AUG. 01, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT, ON AUGUST 1, 2025, THE COMPENSATION COMMITTEE OF TAYSHA'S BOARD OF DIRECTORS GRANTED ONE NEW EMPLOYEE AN OPTION TO PURCHASE 90,000 SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THEIR EMPLOYMENT. THE STOCK OPTION WAS GRANTED UNDER THE TAYSHA GENE THERAPIES, INC. 2023 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE INDIVIDUAL ENTERING EMPLOYMENT WITH TAYSHA IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

DALLAS, JULY 03, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT, ON JULY 1, 2025, THE COMPENSATION COMMITTEE OF TAYSHA'S BOARD OF DIRECTORS GRANTED TWO NEW EMPLOYEES, IN THE AGGREGATE, OPTIONS TO PURCHASE 30,000 SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THEIR EMPLOYMENT. THE STOCK OPTIONS WERE GRANTED UNDER THE TAYSHA GENE THERAPIES, INC. 2023 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE INDIVIDUALS ENTERING EMPLOYMENT WITH TAYSHA IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

DALLAS, JUNE 06, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT, ON JUNE 2, 2025, THE COMPENSATION COMMITTEE OF TAYSHA'S BOARD OF DIRECTORS GRANTED TWO NEW EMPLOYEES, IN THE AGGREGATE, OPTIONS TO PURCHASE 401,000 SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THEIR EMPLOYMENT. THE STOCK OPTIONS WERE GRANTED UNDER THE TAYSHA GENE THERAPIES, INC. 2023 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE INDIVIDUALS ENTERING EMPLOYMENT WITH TAYSHA IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

RECENTLY DISCLOSED CLINICAL COHORT DATA FROM HIGH (1X10 15 TOTAL VG) AND LOW DOSE (5.7X10 14 TOTAL VG) TSHA-102 FROM REVEAL ADOLESCENT/ADULT AND PEDIATRIC PHASE 1/2 TRIALS

TAYSHA GENE THERAPIES ANNOUNCES DETAILS FOR ORAL PRESENTATIONS AT THE 2025 IRSF RETT SYNDROME SCIENTIFIC MEETING REVIEWING RECENT UPDATES FROM THE TSHA-102 CLINICAL PROGRAM

Taysha Gene Therapies, Inc.

TSHA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Taysha Gene Therapies, Inc.

TSHA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TSHA